What is Kisspeptina 5MG & 10MG

Kisspeptina 5MG & 10MG is a neurohormonal decapeptide studied in research as a master regulator of the reproductive axis and a potential stimulator of endogenous sex hormones. It is intended exclusively for research use.

Regarding its chemical identity, Kisspeptina has a molecular formula of C63H83N17O14 and a molecular weight of 1302.5 g/mol. Its reported canonical sequence is Tyr-Asn-Trp-Asn-Ser-Phe-Gly-Leu-Arg-Phe-NH2 (Kisspeptin-10). A confirmed CAS number is not available in open primary reference sources and is therefore omitted.

Its synonyms include Kisspeptina.

Product for research use.

Mechanism of action of Kisspeptina

Kisspeptin-10 acts as the primary agonist for the KISS1R (GPR54) receptor in the hypothalamus. Its activation directly triggers the release of Gonadotropin-Releasing Hormone (GnRH), which in turn cascades into the release of LH and FSH, stimulating testosterone or estrogen production.

Pharmacokinetics and pharmacodynamics of Kisspeptina

Kisspeptin-10 has a very short plasma half-life (minutes), acting as an acute trigger for the reproductive axis. Its short duration necessitates specific timing in research protocols to effectively map the pulsatile release of GnRH.

Scientific evidence on Kisspeptina

The available evidence on Kisspeptina is preliminary and largely inconclusive, and should be interpreted with caution. The literature describes it as having been investigated for multiple indications in preclinical models.

Investigated in models of hypogonadotropic hypogonadism, infertility, and metabolic regulation. Evidence suggests it can successfully override certain forms of reproductive suppression and stimulate natural hormonal cascades without causing testicular shutdown.

Kisspeptina applications in research

Ideal for (research context):
– In vitro and preclinical studies of its specific receptor pathways.
– Investigation of tissue repair, cell proliferation, and functional restoration in laboratory models.
– Comparative work with related peptides.

Not applicable for:
– clinical, diagnostic or therapeutic use.
– Any administration to humans or animals outside of an authorized research protocol.

Product for research use.

Kisspeptina protocols in preclinical studies

The literature consulted does not include numerical doses from studies that can be cited for Kisspeptina, so no trial schemes or quantities are specified.

The presentations of this product (5MG & 10MG) refer only to the amount of lyophilized peptide per vial (or volume for liquids) and do not constitute a dosage recommendation. The design of any protocol, including concentrations and working volumes, is the responsibility of the researcher, based on their experimental objectives and the relevant primary literature.

Information provided exclusively for research purposes.

Reconstitution and manipulation of Kisspeptina

As a general guideline for laboratory handling, lyophilized peptides such as Kisspeptina are usually reconstituted with bacteriostatic water (sterile water with approximately 0.9% benzyl alcohol).

Add the solvent slowly down the side of the vial, letting it run over the lyophilized powder; avoid injecting the stream directly onto the powder.
Do not shake: gently rotate the vial until completely dissolved.
Adjust the solvent volume according to the desired working concentration, considering the 5MG & 10MG contents of the vial.

These guidelines are for general technique and do not replace the internal procedures of each laboratory.

Kisspeptina Stability and Storage

As a standard laboratory handling procedure for peptides:

Freeze-dried (unreconstituted): This is the most stable form. It is best preserved by freezing and protecting it from moisture and light for long-term storage.
Reconstituted: once in solution, the peptide is less stable and must be kept refrigerated, being used within a short period; for extended storage, freezing in aliquots is usually preferred.
Avoid repeated freeze-thaw cycles, as they can degrade the peptide.

Given that the molecule is characterized by rapid enzymatic degradation in biological media, careful cold chain management is especially relevant.

Documented Kisspeptina security profile

The documented safety information in open sources for Kisspeptina is limited and should be interpreted with caution, also considering that it is research material and not for clinical use.

Because it stimulates the natural hormonal pathway, it carries the theoretical risks of any hormone-stimulating therapy, including hormonal imbalances. However, unlike exogenous testosterone, it does not suppress the HPTA (Hypothalamic-Pituitary-Testicular Axis).

Formal contraindications and adverse event rates are not available in the consulted literature, so no figures are reported.

Kisspeptina in a comparative context

Compared to HCG (which mimics LH directly), Kisspeptin acts higher up the chain by stimulating GnRH. This preserves the entire natural cascade of the HPTA, making it a subject of intense research for reversing hypogonadism without suppressive side effects.

History and development of Kisspeptina

Originally discovered in Hershey, Pennsylvania (hence named after Hershey’s Kisses) as a metastasis suppressor gene (KISS1) in melanoma. Its role as the supreme gatekeeper of mammalian reproduction and puberty was only discovered years later.